TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA

Completed

• Conditions: andere ziekten gepaard met lymfeklier vergroting; Fever; lymph node enlargment; lymphoma; 10025319; 10002252

• Registration Number: NL-OMON45645
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Age * 18 years;
- Ability to give written informed consent;
And one of the following:
(1) Lymph node enlargement of unknown cause for whicha diagnostic fine needle aspiration will be performedor
(2) Presenting with fever at the emergency department or
(3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups):
- Ineligibility to give written informed consent;
- Patients with active atopic disease or hepatic failure;
- Patients already diagnosed with Hodgkin lymphoma

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Mean TARC levels (pg/mL) in correlation with final diagnosis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>